Chronic Pain Health — 28 July 2012

A Swedish pharmaceutical company says it will soon seek approval from the U.S. Food and Drug Administration for a new medication to treat opioid dependency. Two clinical trials have been completed on the drug, called OX219, and Orexo says it received “positive feedback” about the studies during a meeting this month with the FDA.

“It is very good news for Orexo. Our meeting with FDA was constructive and we received a general confirmation of the approaches we have taken in developing OX219 for the U.S. market,” says Anders Lundström, CEO of Orexo. “And it is also very good news for the two million people, who suffer from dependency of opioid painkillers in the U.S. Many are not treated today and I do think that we can offer a good alternative to the current treatment.”

FIGHT THE PAIN Visa Prepaid Card Ad 3 V1Currently the only oral drug available on the U.S. market to treat opioid addiction is Suboxone. Like Suboxone, OX219 contains the opioid buprenorphine, combined with naloxone to prevent abuse. The opioid effects of Suboxone are limited and the drug is used to wean addicts from more powerful narcotics such as Vicodin, OxyContin, oxycodone, and hydrocodone. Naloxone is added to Suboxone to block opioid receptors in the brain and central nervous system.

Orexo claims its formulation is superior to Suboxone because the OX219 tablet is smaller, dissolves faster and has a better taste.

When asked to compare OX219 to Suboxone, 77 percent of the participants in one study (41 out of 53) preferred OX219. From previous market research and experience, Orexo says it has learned that taste, mouth feel and dissolve time are important attributes for oral drug delivery, which can influence patient compliance to treatment.

Providing an alternative to Suboxone could be lucrative for Orexo. Suboxone sales reached $1.3 billion in the U.S. in 2011 and sales continued to rise by 12.1% during the first quarter of 2012.

Orexo estimates sales of OX219 in the U.S. could reach $300 to $500 million annually.

According to Orexo, the FDA said its two clinical studies of OX219 were adequate to support a new drug application and no further studies were needed. The company still needs to submit technical information about production of the drug at a U.S.manufacturing facility. Orexo said it would complete technical documentation during the third quarter of 2013.

Orexo, which is headquartered in Uppsala, Sweden, is an emerging specialty pharmaceutical company that specializes in drug reformulations.


About Author

Pat Anson, Editor

Pat is Editor in Chief of American News Report. He is a veteran journalist and a former correspondent and producer for HealthWeek (PBS), Nightly Business Report (PBS) and other nationally syndicated shows. Pat has won numerous journalism awards, including a Golden Mike award for investigative reporting.

(3) Readers Comments

  1. Can this also be abused by crushing and snorting? If so it soon will have a street value as Suboxone has. Addicts turned from trying to find Pain Pill mills to seek out addiction clinics they can make one Suboxone last several days keep what they need to get their fix and then sell the rest from $20 to $30.00 a pill Maine they get $50.00 a pill on the streets from what I read online. If they are prescribed 90 pills a month keep 15 to 20 for themselves. Lets do the math…$25.00(each suboxons) x 70 Suboxone= $1,750- $250.00 monthly doctor visit(Kentucky prices here)= $1,500.00 – $450.00(90 subs x $5.00 each@ pharmacy)= $1,050.00 NET PROFIT monthly for one Pill ADDICT who has found a more profitable drug many places like employers and parole officer do not drug test for. No wonder so many addicts are not working legit jobs they are running a drug business and they take it very serious.

  2. Your article greatly understates the abuse potential of this narcotic. The manufacturer states that when taken with other depressants like benzodiazepines, Suboxone’s ceiling effect on respiratory depression disappears and Suboxone acts like any other narcotic. There is a growing serious epidemic of buprenorphine misuse on the streets. We found that people using the drug on the street often combine it with other drugs. Checkout our recently published research on the emerging epidemic of buprenorphgine in the U.S. in the Journal of Addictive Diseases.